Effects of switching from tamoxifen to anastrozole on tamoxifen-related endocrine symptoms and quality of life: In early breast cancer patients

American Journal of Cancer

Volumn 5, Issue 6, 2006, Pages 433-440

  Massacesi, Cristian ^a   Sabbatini, Elena ^a   Rocchi, Marco B ^b   Zepponi, Laura ^a   Rossini, Simonetta ^a   Pilone, Alberta ^a   Burattini, Luciano ^a   Pezzoli, Marco ^a  

^a OSPEDALI RIUNITI   (Italy)

^b UNIVERSITY OF URBINO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; CA 125 ANTIGEN; TAMOXIFEN;

ABDOMINAL PAIN; ACUTE HEART INFARCTION; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANALYSIS OF VARIANCE; ARTHRITIS; ARTICLE; BONE PAIN; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOMA IN SITU; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY CANCER; EDEMA; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FEMALE; FIBROMATOSIS; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL SYMPTOM; HEART MUSCLE ISCHEMIA; HUMAN; LEG THROMBOSIS; LEUKOPENIA; MENOPAUSAL SYNDROME; MYALGIA; PATIENT COMPLIANCE; PHLEBITIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SAMPLE SIZE; SIDE EFFECT; STANDARD; STATISTICAL SIGNIFICANCE; SYMPTOM; TASTE; TREATMENT DURATION; TREATMENT OUTCOME; UTERINE FIBROMATOSIS; UTERUS DISEASE;

EID: 33846874094     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200605060-00009     Document Type: Article

References (22)

1. Goldhirsch A, Wood WC, Gelber RD, et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21 (17): 3357-65
2. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351 (9114): 1451-67
3. Koberle D, Thurlimann B. Adjuvant endocrine therapy in postmenopausal breast cancer patients. Breast 2005; 14 (6): 446-51
4. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004; 11 (4): 643-58
5. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359 (9324): 2131-9
6. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003; 98 (9): 1802-10
7. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349 (19): 1793-802
8. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365 (9453): 60-2
9. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353 (26): 2747-57
10. Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005; 23 (22): 5138-47
11. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350 (11): 1081-92
12. Fallowfield L. Acceptance of adjuvant therapy and quality of life issues. Breast 2005; 14 (6): 612-6
13. Fallowfield L, Cella D, Cuzick J, et al. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) adjuvant breast cancer trial. J Clin Oncol 2004; 22 (21): 4261-71
14. National Cancer Institute [online]. Available from URL: http://ctep.cancer.gov [Accessed 2006 Nov 6]
15. Functional Assessment of Chronic Illness Therapy [online]. Available from URL: http://www.facit.org [Accessed 2006 Nov 6]
16. Bonomi AE, Cella DF, Hahn EA, et al. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Qual Life Res 1996; 5 (3): 309-20
17. Cella DF, Tulsky DS, Gray G, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11 (3): 570-9
18. Brady MJ, Cella DF, Mo F, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 1997; 15 (3): 974-86
19. Fallowfield LJ, Leaity SK, Howell A, et al. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat 1999; 55 (2): 189-99
20. Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998; 16 (1): 139-44
21. Fallowfield LJ, Price MH, Hall E, et al. Intergroup exemestane study: results of the quality of life sub-protocol [abstract no. 4]. Breast Cancer Res Treat 2004; 88 Suppl. 1: S8
22. Fallowfield LJ, Bliss JM, Porter LS, et al. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 2006; 24 (6): 910-7